WO2005005603A3 - Method for inducing an immune response to cancer antigen - Google Patents

Method for inducing an immune response to cancer antigen Download PDF

Info

Publication number
WO2005005603A3
WO2005005603A3 PCT/US2004/018441 US2004018441W WO2005005603A3 WO 2005005603 A3 WO2005005603 A3 WO 2005005603A3 US 2004018441 W US2004018441 W US 2004018441W WO 2005005603 A3 WO2005005603 A3 WO 2005005603A3
Authority
WO
WIPO (PCT)
Prior art keywords
host
cells
cancer antigen
immune response
antigen
Prior art date
Application number
PCT/US2004/018441
Other languages
French (fr)
Other versions
WO2005005603A2 (en
Inventor
Diane E Epperson
Gregory M Glenn
Scott A Hammond
Original Assignee
Iomai Corp
Diane E Epperson
Gregory M Glenn
Scott A Hammond
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iomai Corp, Diane E Epperson, Gregory M Glenn, Scott A Hammond filed Critical Iomai Corp
Publication of WO2005005603A2 publication Critical patent/WO2005005603A2/en
Publication of WO2005005603A3 publication Critical patent/WO2005005603A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

An immune response is induced in a host by expressing at least one nonself (i.e., foreign) major histocompatibility complex (MHC) Class II molecule on host antigen presenting cells (APC) to stimulate host CD4+ T cells and presenting at least one oligopeptide of a cancer antigen to naive host CD8+ T cells. From these priming events, the development of a cancer antigen-specific cytotoxic reaction in the host may be dependent on or enhanced by help provided by the CD4+ T cells. A method for immunization is comprised of (1) at least one foreign MHC Class II molecule and (2) at least one tumor antigen having an amino acid sequence with at least one self MHC Class I-restricted oligopeptide therein. Adjuvant is an optional component of the system.
PCT/US2004/018441 2003-06-10 2004-06-10 Method for inducing an immune response to cancer antigen WO2005005603A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47705603P 2003-06-10 2003-06-10
US60/477,056 2003-06-10

Publications (2)

Publication Number Publication Date
WO2005005603A2 WO2005005603A2 (en) 2005-01-20
WO2005005603A3 true WO2005005603A3 (en) 2005-10-20

Family

ID=34061910

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/018441 WO2005005603A2 (en) 2003-06-10 2004-06-10 Method for inducing an immune response to cancer antigen

Country Status (1)

Country Link
WO (1) WO2005005603A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020085991A1 (en) * 2000-03-14 2002-07-04 Keith Ainsley Selected mixture for animal lure
US6465251B1 (en) * 1996-11-13 2002-10-15 Dana-Farber Cancer Institute, Inc. Method of promoting b-cell proliferation and activation with CD40 ligand and cyclosporin
US6472375B1 (en) * 1998-04-16 2002-10-29 John Wayne Cancer Institute DNA vaccine and methods for its use
US20030235594A1 (en) * 1999-09-14 2003-12-25 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465251B1 (en) * 1996-11-13 2002-10-15 Dana-Farber Cancer Institute, Inc. Method of promoting b-cell proliferation and activation with CD40 ligand and cyclosporin
US6472375B1 (en) * 1998-04-16 2002-10-29 John Wayne Cancer Institute DNA vaccine and methods for its use
US20030235594A1 (en) * 1999-09-14 2003-12-25 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines
US20020085991A1 (en) * 2000-03-14 2002-07-04 Keith Ainsley Selected mixture for animal lure

Also Published As

Publication number Publication date
WO2005005603A2 (en) 2005-01-20

Similar Documents

Publication Publication Date Title
Shibaki et al. Induction of skewed Th1/Th2 T‐cell differentiation via subcutaneous immunization with Freund's adjuvant
De Titta et al. Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose
Joosten et al. Harnessing donor unrestricted T-cells for new vaccines against tuberculosis
WO1998033527A3 (en) Cancer immunotherapy with semi-allogeneic cells
AU7980794A (en) Methods and compositions for microencapsulation of antigens for use as vaccines
Bou Nasser Eddine et al. CIITA-driven MHC class II expressing tumor cells can efficiently prime naive CD4+ TH cells in vivo and vaccinate the host against parental MHC-II-negative tumor cells
WO2002058723A3 (en) Chemokines as adjuvants of immune response
BR9811037A (en) Use of mhc class ii ligands as an adjuvant for vaccination and lag-3 in cancer treatment
WO2005000348A3 (en) Vaccines inducing nkt-cell and toll-like-receptor activation
DK1267924T3 (en) Immunotherapeutic methods and compositions
WO1998058956A3 (en) Methods for inducing an immune response involving prime-boost protocols
Crowley et al. Neoleukin-2 enhances anti-tumour immunity downstream of peptide vaccination targeted by an anti-MHC class II VHH
ATE399022T1 (en) COMPOSITION AND METHOD FOR ENHANCING THE IMMUNE RESPONSE OF ANTIGEN-PRESENTING CELLS
WO2003033520A3 (en) Anticancer vaccine and diganostic methods and reagents
WO2003011331A3 (en) Materials and methods relating to improved vaccination strategies
Hartl et al. DNA vaccines for allergy treatment
WO2004053095A3 (en) In situ maturation of dendritic cells
WO2005005603A3 (en) Method for inducing an immune response to cancer antigen
NZ507829A (en) Vaccine adjuvants for immunotherapy of melanoma
WO1997011669A3 (en) MHC-class II restricted melanoma antigens and their use in therapeutic methods
WO2006072787A8 (en) Compositions for immunizing against mycobacterium
He et al. Antigen epitope-expressing cytokines for DNA immunization
SI1833507T1 (en) Compositions for immunizing against mycobacterium
WO1999047102A3 (en) Methods for enhanced antigen presentation on antigen-presenting cells and compositions produced thereby
WO2004033667A3 (en) Detection, localization and staging of tumors using labeled activated lymphocytes directed to a tumor specific epitope

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase